If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including:

• 11 FDA-approved Abbreviated New Drug Application (ANDA) products for the U.S. market
• Multiple ANDAs currently filed with the U.S. Food and Drug Administration awaiting approval
• Additional generic products in development